Search research articles
Contact Us
Filters
Showing results (121-130 of 131) with videos related to
Page
of 14
Sort By:
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
March 14, 2001
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management
E J Dippel, D J Kereiakes, D A Tramuta, et al.
American Heart Journal
|
February 22, 2003
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention
Mark I Furman, Dean J Kereiakes, Lori A Krueger, et al.
American Heart Journal
|
October 31, 2001
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab
M I Furman, D J Kereiakes, L A Krueger, et al.
Circulation
|
September 30, 1998
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial
D J Kereiakes, N S Kleiman, J J Ferguson, et al.
American Heart Journal
|
September 30, 2000
Abciximab provides cost-effective survival advantage in high-volume interventional practice
D J Kereiakes, R L Obenchain, B L Barber, et al.
Nature Communications
|
June 11, 2026
Influenza coinfection inhibits control of mycobacterial infection in a human challenge model
Claire M Broderick, Oliver Powell, Sam Nichols, et al.
Lancet (London, England)
|
September 30, 2018
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial
Gregg W Stone, Stephen G Ellis, Tommaso Gori, et al.
BMC Pulmonary Medicine
|
November 22, 2015
A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
Yong Huang, Shwu-Fan Ma, Rekha Vij, et al.
Environmental Microbiome
|
August 2, 2024
From soil to sequence: filling the critical gap in genome-resolved metagenomics is essential to the future of soil microbial ecology
Winston E Anthony, Steven D Allison, Caitlin M Broderick, et al.
The Lancet. Respiratory Medicine
|
January 17, 2014
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
Imre Noth, Yingze Zhang, Shwu-Fan Ma, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 131) with videos related to
Sort By:
Page
of 14
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|
March 14, 2001
Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management
E J Dippel, D J Kereiakes, D A Tramuta, et al.
American Heart Journal
|
February 22, 2003
Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention
Mark I Furman, Dean J Kereiakes, Lori A Krueger, et al.
American Heart Journal
|
October 31, 2001
Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab
M I Furman, D J Kereiakes, L A Krueger, et al.
Circulation
|
September 30, 1998
Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial
D J Kereiakes, N S Kleiman, J J Ferguson, et al.
American Heart Journal
|
September 30, 2000
Abciximab provides cost-effective survival advantage in high-volume interventional practice
D J Kereiakes, R L Obenchain, B L Barber, et al.
Nature Communications
|
June 11, 2026
Influenza coinfection inhibits control of mycobacterial infection in a human challenge model
Claire M Broderick, Oliver Powell, Sam Nichols, et al.
Lancet (London, England)
|
September 30, 2018
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial
Gregg W Stone, Stephen G Ellis, Tommaso Gori, et al.
BMC Pulmonary Medicine
|
November 22, 2015
A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
Yong Huang, Shwu-Fan Ma, Rekha Vij, et al.
Environmental Microbiome
|
August 2, 2024
From soil to sequence: filling the critical gap in genome-resolved metagenomics is essential to the future of soil microbial ecology
Winston E Anthony, Steven D Allison, Caitlin M Broderick, et al.
The Lancet. Respiratory Medicine
|
January 17, 2014
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
Imre Noth, Yingze Zhang, Shwu-Fan Ma, et al.
Page
of 14